Japanese trial compared lytics for bridging before endovascular thrombectomy ...

Recent research has revealed compelling evidence supporting tenecteplase as a more effective treatment for ischemic strokes compared to traditional alteplase therapy. This discovery could mark a major ...

Please provide your email address to receive an email when new articles are posted on . The study included 72 individuals with ischemic stroke given alteplase and tenecteplase. No significant time ...

Tenecteplase given 4.5-24 hours post-stroke does not boost functional outcomes in patients with occlusions of the internal carotid artery or M1 or M2 segments of the middle cerebral artery who showed ...

Tenecteplase, a genetically modified tissue plasminogen activator derived from alteplase, has recently been shown to be as effective and safe as alteplase for the treatment of acute ischemic stroke.

Making the switch from alteplase to tenecteplase for stroke thrombolysis can be done successfully when the appropriate preparations are taken, and it may improve patient outcomes, the experience of a ...

TNKase is administered as a single intravenous bolus over 5 seconds. The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in ...

Please provide your email address to receive an email when new articles are posted on . The findings were presented in a poster at the American College of Allergy, Asthma & Immunology Annual ...

Whether the evidence supports wider use of tenecteplase (TNKase; Genentech)—a thrombolytic agent with an indication for acute MI—as an alternative to alteplase (Activase; Genentech) for the treatment ...

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase), a thrombolytic or clot-dissolving agent, for the ...